ArticleCommunications medicine2026
Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.Communications medicine · 2026Article
Corrections and comments
- Update of
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate diagnosis of hematologic malignancies from peripheral blood smears (PBSs) requires integrating cellular morphology and composition across numerous white blood cells. Existing computational approaches predominantly automate single-cell classifications and do not provide holistic, slide-level diagnostic predictions.
methodsWe present a framework that employs a high-performance cell-based encoder (DeepHeme) for feature extraction, integrated with our weakly supervised, attention-based multiple instance learning (MIL) model, termed CAREMIL (Cell AggRegation, Explainable, Multiple Instance Learning). Through comprehensive evaluations of leading image encoders and MIL architectures, the combination of DeepHeme and CAREMIL demonstrated superior performance on disease classification tasks. CAREMIL functions as a robust aggregation mechanism, consistently outperforming established slide-level MIL methods (gated MIL and Dual-stream MIL Network) across multiple encoder types. The most pronounced performance gains were observed with out-of-domain encoders, including ImageNet-pretrained and open-source pathology foundation models (UNI2 and Virchow2).
resultsCAREMIL combined with DeepHeme achieves the highest diagnostic accuracy across acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and hairy cell leukemia (HCL), with AUROCs of 0.999, 0.891, and 0.945, respectively, and successfully identifies AML even in cases with minimal or absent circulating blasts. Attention values assigned by CAREMIL highlight diagnostically relevant cells and reveal disease-specific morphometric patterns, enabling biological interpretability and case-level insights. The framework remains resilient to individual cell misclassifications and does not require explicit cell-level supervision.
conclusionsThese findings establish CAREMIL as an effective and interpretable MIL framework for hematologic slide diagnosis, extendable to bone marrow aspirates, cytology, and other liquid biopsy specimens, supporting a shift toward quantitative, morphology-informed hematologic diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.